{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009949","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.455054+00:00","generated_at":"2026-05-21T16:37:06.744010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate","bullets":["Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.","Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.","PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.","U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.","Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009949","json":"https://secwatch.observer/filing/0001641172-25-009949.json","markdown":"https://secwatch.observer/filing/0001641172-25-009949.md","text":"https://secwatch.observer/filing/0001641172-25-009949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/0001641172-25-009949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:37:06.744010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}